Seroepidemiology of measles in Beijing, China: a cross-sectional study.
Measles
Seroprevalence
Journal
Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652
Informations de publication
Date de publication:
2019
2019
Historique:
pubmed:
23
5
2019
medline:
4
3
2020
entrez:
23
5
2019
Statut:
ppublish
Résumé
The aim of this study was to assess the seroprevalence of measles and identify the high risk of measles infection in the general population of Beijing. A total of 2144 subjects aged 0-76 years old were selected using a multi-stage stratified sampling method. Socio-demographic characteristics, vaccination history, and disease history of measles were collected by questionnaire. Serum samples were tested for measles-specific IgG by using commercial ELISA kits. The overall seropositivity rate of measles was 79.80% (95% CI 78.1-81.5%) and standardized seropositivity rate was 84.61% (95% CI 84.12-87.10%), with the median concentration of 773.40IU/L. The area of Beijing with the highest seroprevalence was the central area [81.79% (95% CI 80.16-83.42%) and 855.84IU/L]. There were no significant differences in seropositivity rates of different genders (P = 0.074), history of measles infection (P = 0.421) and registered population (P = 0.598). The 1-4 age group had the highest seropositivity rate [94.06%(95% CI 93.06-95.06%)] and children below the age of 1 (0-12 months) had the lowest seropositivity rate [34.42% (95% CI 32.41-36.43%)]. The 30-34 and 35-39 age groups were relatively lower with 72.90% (95% CI 71.02-74.78%) and 74.65% (95% CI 72.81-76.49%) respectively. Seropositivity rates changed along with the incidence rates of measles periodically by years. As shown in the present study, the seroprevalence of measles antibody in Beijing have not yet met the threshold required to achieve measles elimination and therefore the risk of an epidemic of measles will be existing. Appropriate targeted immunization strategies and measures should be considered and carried out.
Identifiants
pubmed: 31116635
doi: 10.1080/21645515.2019.1581527
pmc: PMC6773410
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2112-2116Références
Clin Infect Dis. 2011 Apr 1;52(7):911-6
pubmed: 21427399
Zhonghua Yu Fang Yi Xue Za Zhi. 2016 Jul 6;50(7):615-9
pubmed: 27412838
Am J Epidemiol. 1983 Jan;117(1):2-13
pubmed: 6337476
J Infect Dis. 2004 May 1;189 Suppl 1:S27-35
pubmed: 15106086
Vaccine. 2017 May 19;35(22):2925-2929
pubmed: 28433329
Wkly Epidemiol Rec. 2009 Jul 3;84(27):271-9
pubmed: 19579325
Vaccine. 2018 Jan 25;36(4):507-513
pubmed: 29269156
Vaccine. 2012 Sep 7;30(41):5905-13
pubmed: 22841972
J Infect Dis. 2007 Nov 15;196(10):1459-64
pubmed: 18008224
Zhonghua Yu Fang Yi Xue Za Zhi. 2013 Oct;47(10):916-9
pubmed: 24378131